Alto Neuroscience Files Q1 2024 10-Q Report
Ticker: ANRO · Form: 10-Q · Filed: 2024-05-14T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Alto Neuroscience filed its Q1 2024 10-Q, check financials.
AI Summary
Alto Neuroscience, Inc. filed its quarterly report for the period ending March 31, 2024. The company, operating in the pharmaceutical preparations sector, reported its financial status and business activities. Key financial data and operational details are presented in this filing.
Why It Matters
This filing provides investors and stakeholders with an update on Alto Neuroscience's financial health and operational progress during the first quarter of 2024.
Risk Assessment
Risk Level: medium — As a clinical-stage company in the pharmaceutical sector, Alto Neuroscience faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 2024-05-14 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Filer of the 10-Q report
- 20240331 (date) — End of the reporting period
- 20240514 (date) — Filing date of the report
- 2834 (other) — Standard Industrial Classification code for Pharmaceutical Preparations
FAQ
What is the primary business of Alto Neuroscience, Inc.?
Alto Neuroscience, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
For what period is this 10-Q report filed?
This 10-Q report is filed for the period ending March 31, 2024.
When was this 10-Q report filed with the SEC?
The report was filed on May 14, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 369 South San Antonio Rd., Los Altos, CA 94022.
What is Alto Neuroscience's fiscal year end?
Alto Neuroscience's fiscal year ends on December 31.
From the Filing
0001999480-24-000022.txt : 20240514 0001999480-24-000022.hdr.sgml : 20240514 20240514163255 ACCESSION NUMBER: 0001999480-24-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 24945002 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 10-Q 1 alto-20240331.htm 10-Q alto-20240331 12-31 0001999480 2024 Q1 False 0.4462 xbrli:shares iso4217:USD iso4217:USD xbrli:shares alto:subsidiary alto:clinical-stageAsset utr:Rate alto:tranche alto:loan xbrli:pure alto:invention alto:patentFamily 0001999480 2024-01-01 2024-03-31 0001999480 2024-05-10 0001999480 2024-03-31 0001999480 2023-12-31 0001999480 2023-01-01 2023-03-31 0001999480 2023-03-31 0001999480 2022-12-31 0001999480 us-gaap:CommonStockMember 2022-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001999480 us-gaap:RetainedEarningsMember 2022-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001999480 alto:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001999480 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001999480 us-gaap:CommonStockMember 2023-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001999480 us-gaap:RetainedEarningsMember 2023-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001999480 us-gaap:CommonStockMember 2023-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001999480 us-gaap:RetainedEarningsMember 2023-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001999480 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001999480 us-gaap:IPOMember 2024-01-01 2024-03-31 0001999480 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001999480 us-gaap:CommonStockMember 2024-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001999480 us-gaap:RetainedEarningsMember 2024-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001999480 us-gaap:IPOMember 2023-01-01 2023-03-31 0001999480 alto:SeriesCPreferredStockFinancingMember 2024-01-01 2024-03-31 0001999480 alto:SeriesCPreferredStockFinancingMember 2023-01-01 2023-03-31 0001999480 2023-01-01 2023-01-31 0001999480 us-gaap:IPOMember 2024-02-06 2024-02-06 0001999480 us-gaap:IPOMember 2024-02-06 0001999480 us-gaap:OverAllotmentOptionMember 2024-02-06 2024-02-06 0001999480 2024-01-01 2024-01-31 0001999480 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001999480 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001999480 alto:ComputerSoftwareAndEquipmentMember 2024-03-31 0001999480 alto:ComputerSoftwareAndEquipmentMember 2023-12-31 0001999480 alto:LaboratoryEquipmentMember 2024-03-31 0001999480 alto:LaboratoryEquipmentMember 2023-12-31 0001999480 us-gaap:SecuredDebtMember alto:LoanAndSecurityAgreementMember 2022-12-16 0001999480 alto:DebtInstrumentTrancheOneMember us-gaap:SecuredDebtMember alto:LoanAndSecurityAgreementMember 2022-12-16 0001999480 us-gaap:SecuredDebtMember alto:LoanAndSecurityAgreementMember alto:DebtInstrumentTrancheTwoMember 2022-12-16 0001999480 us-gaap:SecuredDebtMember alto:LoanAndSecurityAgreeme